Abstract
Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Current Enzyme Inhibition
Title: Arachidonic Acid Cascade Enzyme Inhibition and Cancer
Volume: 1 Issue: 2
Author(s): J. J. Moreno
Affiliation:
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Abstract: Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Export Options
About this article
Cite this article as:
Moreno J. J., Arachidonic Acid Cascade Enzyme Inhibition and Cancer, Current Enzyme Inhibition 2005; 1 (2) . https://dx.doi.org/10.2174/1573408054022261
DOI https://dx.doi.org/10.2174/1573408054022261 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Oxidative Biotransformation of Fatty Acids by Cytochromes P450: Predicted Key Structural Elements Orchestrating Substrate Specificity, Regioselectivity and Catalytic Efficiency
Current Drug Metabolism Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Diversity-Oriented Synthetic Approaches for Furoindoline: A Review
Current Organic Synthesis Preface [Hot Topic: Arachidonic Acid Cascade Modulators: The Cyclooxygenase Pathway (Executive Editors: Jean-Michel Dogné / Xavier de Leval)]
Mini-Reviews in Medicinal Chemistry Regulation of V-ATPase Expression in Mammalian Cells
Current Protein & Peptide Science Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Current Perspectives in Prostate Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: The Role of Cytokines in Neurodegeneration and Psychiatric Conditions: Multiple Mechanisms of Action (Executive Editor: Shawn Hayley)]
Current Pharmaceutical Design Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses
Current Medicinal Chemistry Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cardioprotection with opioids - Trusted old friends -Clinical Science -
Current Pharmaceutical Design Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews Selective PGHS-2 Inhibitors: A Rational Approach for Treatment of the Inflammation
Medicinal Chemistry Reviews - Online (Discontinued) Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry Nucleic Acids Electro-transfer: From Bench to Bedside
Current Drug Metabolism The Adiponectin Signaling Pathway as a Novel Pharmacological Target
Mini-Reviews in Medicinal Chemistry